Personalis and Tempus AI are adding colorectal cancer as a new indication to their existing commercialization agreement.

Frontier Capital Management, an investment management company, released its “Frontier Small Cap Growth Fund” first quarter ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, ...

Tempus AI will collaborate with Northwestern University's neurogenomics researchers to use artificial intelligence to accelerate discovery of treatments for Alzheimer's disease, the Chicago-based ...

In the weeks since the report, however, Tempus' shares have rebounded and as markets closed yesterday, they were trading 4% higher than their closing price the day before the report. Short sellers ...

Tempus AI TEM continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in TD Cowen's ...

CHICAGO, June 12, 2025--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in TD Cowen's/Securities' 4th Annual Tools/Dx ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tempus AI's whale activity within a strike price range from $64.0 to $120.0 in the ...